Browsing by Author Lee, Chee

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 14 of 14
Issue DateTitleAuthor(s)Citation
2011Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancerBrown, Christopher; Gebski, Val; Gurney, Howard; Lee, Chee; Lord, Sarah (Sally); Simes, Robert John; Bacon, M; Donadello, Nicoletta; Friedlander, Michael; Maenpaa, J; Meier, W; Petru, E; Pujade-Lauraine, Eric; Reed, N; Sorio, R; Tulunay, G; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead); School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCarboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer, British Journal of Cancer, vol.105, 3, 2011,pp 360-365
2011Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer.Brown, Christopher; Gebski, Val; Lee, Chee; Lord, Sarah (Sally); Simes, Robert John; Delva, Remy; Donadello, Nicoletta; Friedlander, Michael L.; Georgoulopoulos, Alexander; Mirza, Mansoor Raza; Pignata, Sandro; Pujade-Lauraine, Eric; Schmalfeldt, Barbara; Southier, Philippe; Vergote, Ignace; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreEarly Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer., Journal of the National Cancer Institute, vol.103, 17, 2011,pp 1338-1342
2012Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysisHoward, Kirsten; Lee, Chee; Lord, Sarah (Sally); Martin, Andrew; Simes, Robert John; Verry, Hannah; Gill, Grantley; Wetzig, Neil R; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreEffectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis, British Journal of Cancer, vol.106, 6, 2012,pp 1045-1052
2010Historical cross-trial comparisons for competing treatments in advanced breast cancer - An empirical analysis of bias.Coates, Alan; Gebski, Val; Lee, Chee; Lord, Sarah (Sally); Simes, Robert John; Stockler, Martin; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreHistorical cross-trial comparisons for competing treatments in advanced breast cancer - An empirical analysis of bias., European Journal of Cancer, vol.46, 3,pp 541-548
2013Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-AnalysisBrown, Christopher; Gebski, Val; Lee, Chee; Chu, Da Tong; et al, Various; Gralla, Richard J; Hirsh, V; Ho, James Chung-Man; Osorio Sanchez, Jemela Anne; Tan, E; Thongprasert, Sumitra; Tsai, Chun-Ming; Vu, VuVan; Zaatar, Adel; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreImpact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis, National Cancer Institute. Journal, vol.105, 9, 2013,pp 595-605
2011Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal CancerCummins, Michelle; Lee, Chee; Chua, Ann; Hardingham, Jennifer; Murone, Carmel; Price, Timothy; Shivasami, Aravind; Tebbutt, Niall C; Townsend, Amanda; Weikhardt, Andrew; Wrin, Joseph; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreImpact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer, Journal of Clinical Oncology, vol.29, 19, 2011,pp 2675-2682
2012Increase in Cholesterol PredictsSsurvival Advantage in Renal Cell Carcinoma Patients Treated with TemsirolimusLee, Chee; Marschner, Ian (Colin); Simes, Robert John; Voysey, Merryn; de Souza, Paul; Egleston, Brian; Hudes, Gary; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreIncrease in Cholesterol PredictsSsurvival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus, Clinical Cancer Research, vol.18, 11, 2012,pp 3188-3196
2013Markers of systemic inflammation predict survival in patients with advanced renal cell cancerBrown, Christopher; Gebski, Val; Lee, Chee; Lord, Sarah (Sally); de Souza, Paul; Fox, P; Hudson, M; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreMarkers of systemic inflammation predict survival in patients with advanced renal cell cancer, British Journal of Cancer, vol.109, 1, 2013,pp 147-153
2009Molecular biomarkers to individualise treatment: assessing the evidenceCoates, Alan; Lee, Chee; Lord, Sarah (Sally); Simes, Robert John; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreMolecular biomarkers to individualise treatment: assessing the evidence, Medical Journal of Australia, vol.190, 11,pp 631-636
2011A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancerAckland, Stephen; Boyle, Frances; Coates, Alan; Friedlander, Michael; Gebski, Val; Hudson, Malcolm; Lee, Chee; Lord, Sarah (Sally); Simes, Robert John; Stockler, Martin; School of Public Health: NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreA nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer, Breast Cancer Research and Treatment, vol.129, 2, 2011,pp 467-476
2013Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumabLee, Chee; Simes, Robert John; Wilson, Katherine; Hardingham, Jennifer; Murone, Carmel; Price, Timothy; Tebbutt, Niall; Townsend, Amanda; Weickhardt, Andrew; Wrin, Joseph; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Science Faculty AdminPrognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab, Cancer Medicine, vol.2, 3, 2013,pp 277-285
2013A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancerBrown, Christopher; Gebski, Val; Lee, Chee; Lord, Sarah (Sally); Simes, Robert John; Baumann, K; Berton-Rigaud, D; et al, Various; Parma, G.; Pfisterer, J; Pisano, C.; Plante, M.; Schauer, C; Skeie-Jensen, T; Swart, Ann Marie; Vergote, I; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreA prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer, Annals of Oncology, vol.24, 4, 2013,pp 937-943
2011Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancerBrown, Christopher; Gebski, Val; Lee, Chee; Lord, Sarah (Sally); Simes, Robert John; Angleitner-Boubenizek, L.; Bentley, J.; Bourgeois, H.; Burges, A.; Ferrero, A.; Friedlander, Michael; Hirte, H.; Hogberg, T.; Parma, G.; Pfisterer, J.; Pisano, C.; Plante, M.; Pujade-Lauraine, Eric; Richter, B.; Vergote, Ignace; Wagner, U.; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentrePrognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer, British Journal of Cancer, vol.105, 8, 2011,pp 1144-1150
2010Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancerCoates, Alan; Gebski, Val; Lee, Chee; Lord, Sarah (Sally); Simes, Robert John; Stockler, Martin; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreSelf-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer, British Journal of Cancer, vol.102, 9,pp 1341-1347